Supplement bij eenentwintigste jaargang, april 2013 Voorjaarsvergadering van de Nederlandse Vereniging voor Medische Microbiologie (NVMM) en de Koninklijke Nederlandse Vereniging voor Microbiologie (KVvM) Ecalta® Als medicatieveiligheid telt • Geen klinisch relevante geneesmiddelen interacties1-5 • Geen dosisaanpassing in verband met gewicht, lever- en nierfunctiestoornissen1-5 Papendal, 16 & 17 april 2013 Programma-overzicht Abstracts Auteursindex Zie voor referenties en productkenmerken elders in deze uitgave 21e jaargang . april 2013 . Supplement 1-5 Doeltreffend en gemakkelijk 12.ECL.21.1 Doeltreffend en gemakkelijk1-7 655957_PFI_AdvEcalta.indd 1 22-02-12 14:50 STRIKE! Evidence. Experience. Confi dence. bij • Invasieve candidiasis1 • Invasieve aspergillose2 • Empirische antifungale therapie3 C. albicans C. rugosaC. glabrataC. parapsilosisC. tropicalisC. kruseiC. guilliermondiiC. lipolyticaC. dubliniensisC. kefyrC. lusitaniaeA. fl avusA. fumigatusA. terreusA. nigerA. nidulans NU VERGOED! CANDIDA ALBICANS CANDIDA NON-ALBICANS ASPERGILLUS Wereldwijd al meer dan • Bewezen effectiviteit1 750.000 patiënten behandeld1 • Gunstig veiligheidsprofi el4 5,6 Hoog gebruiksgemak • Bij volwassenen en kinderen • Geen oplaaddosis2 • Geen dosis aanpassing2 Referenties: 2 1. Mora-Duarte J.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Eng J Med 347;2020-9, 2002. • Geen specifieke bewaarcondities 2. Maertens J.: Effi cacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant 2 for conventional antifungal therapy. CID 2004;39:000-000. 3. Walsh T.J.: Caspofungin versus Liposomal Amphotericin B for Voor alle leeftijden (0-99) empirical antifungal therapy in patients with persistent fever and neutropenia. N Eng J Med 2004; 351:1391-402.4. David W. Denning: Echinocandin antifungal drugs. 362: 1142-51, 2003.5. Walsh TJ: Pharmacokinetics, safety and tolerability The Lancet zie elders in deze uitgave. MYC2011-729 Productinformatie: of caspofungin in children and adolescents. AAC 49: 4536-4545, 2005. 6. Zaoutis TE: A prospective, multicenter study of caspofungin for treatment of documented candida or aspergillus infections in pediatric patients. Pediatrics 123:877-884, 2009. Raadpleeg eerst de volledige productinformatie alvorens CANCIDAS voor te schrijven M Merck Sharp & Dohme BV, Postbus 581, 2003 PC Haarlem Tel. 0800-9999000, email [email protected] 1110CAN09NL539J1109 www.msd.nl, www.univadis.nl Evidence. Experience. Confi dence. Cans539J_Adv_210x297.indd 1 18-02-11 15:40 Organizing committee Poster committee Prof. dr. M.D. de Jong, chair Prof. dr. S. Brul Prof. dr. A.J.W. van Alphen Dr. W. van Schaik Prof. dr. W. Bitter Dr. A.M.J. Wensing Prof. dr. S. Brul Prof. dr. L. Dijkhuizen Dr. B. Duim Dr. J.W.B. van der Giessen Dr. P.J.A. Haas Prof. dr. ir. M.S.M. Jetten Prof. dr. M.P.G. Koopmans Prof. dr. O.P. Kuipers Prof. dr. P. Rottier Prof. dr. P.H.M. Savelkoul Dr. B.J.M. Vlaminckx Prof. dr. ir. M.H. Zwietering The Scientific spring meeting is organized by the Dutch Society of Medical Microbiology (NVMM) and the Royal Dutch Society of Microbiology (KNVM). Meeting secretariat Congress Company P.O. Box 2428 5202 CK ’s-Hertogenbosch Tel 073 - 700 35 00 [email protected] www.congresscompany.com Ned Tijdschr Med Microbiol 2013;21:Supplement S1 PROGRAMME Tuesday ApriL 16, 2013 eXHiBiTiON ROOM ATHeNe B/C ROOM ATHeNe A ROOM 2 ROOM 4/5 ROOM 6/7 ROOM 8/9 09:00 - 09:30 Registration 09:30 - 11:00 Plenary session 11:00 - 11:30 Coffee/tea 11:30 - 12:45 Plenary session & Award Ceremony 12:45 - 14:00 Lunch KNVM Business Meeting 14:00 - 15:30 New challenges in Community acquired Leishmaniasis: a intestinal microbes Microbial pathogenesis 1 Clinical microbiology infection prevention Clostridium difficile curable disease? and host interplay WAMM: Back to the infections: from pigs to roots - diagnostics of humans and vice versa urinary tract infections 15:30 - 16:00 Coffee/tea S2 16:00 - 17:30 Clinical microbiology Bacterial cell growth Campylobacter – Clinical development Highly resistant micro- STD dynamics in host interactions of malaria drugs organisms outside the the Netherlands and and vaccines in the hospital - What can we europe Netherlands expect from nursing homes and public health services? 17:30 - 18:30 Drinks 18:30 - 20:30 Dinner 20:30 - 22:15 Poster session & Poster award ceremony 22:15 - 01:30 Party PROGRAMME Wednesday ApriL 17, 2013 eXHiBiTiON ROOM ATHeNe B/C ROOM ATHeNe A ROOM 2 ROOM 4/5 ROOM 6/7 ROOM 8/9 08:30 - 09:00 Registration 09:00 - 10:30 Viral zoonoses Whole genome Antimicrobial NVMy symposium 1: New human and Finding the needle sequencing in clinical peptides: a rich Detection and veterinary vaccines against in the haystack: microbiology and its appli- source for developing diagnosis tuberculosis molecular diagnostics cations in understanding novel antibiotics of gastro enteritis microbial biology 10:30 - 11:00 Coffee/tea 11:00 - 12:30 NVMy symposium 2: Virology Microbial physiology Computer assisted experimental evolution Microbial patho- epidemiology and teaching genesis 2 treatment 12:30 - 14:00 Lunch 13:00 - 14:00 BBC-MMO Business S3 Meeting 14:00 - 15:30 WMDi: Novel Antimicrobial resistance Horen, zien en Travel-related Genome-associated Progress in approaches in the vooral niet zwijgen diseases biomarkers for vaccines microbiology detection of antimi- (NL-talige sessie) crobial resistance 15:30 - 16:00 Coffee/tea 16:00 - 17:30 NVMM Business Meeting Ned Tijdschr Med Microbiol 2013;21:Supplement Ned Tijdschr Med Microbiol 2013;21:Supplement FLOORPLAN PAPENDAL EXHIBITION ROOMS Ned Tijdschr Med Microbiol 2013;21:Supplement Ned Tijdschr Med Microbiol 2013;21:Supplement S4 S5 Major Sponsor SCIENTIFIC PROGRAMMA MONDAY 15 APRIL 2013 15:00 - 15:30 Infection risks in hospitals: it’s the environment stupid! O006 Jan van Zeijl Room Athene A 13:00 - 17:15 National examination for medical microbiolo- gists in training Athene A Community acquired Clostridium difficile infections: from pigs to humans and vice versa Chair: Ed Kuijper SPONSORS AND EXHIBITORS Restaurant 14:00 - 14:30 Clostridium difficile infections outside 19:00 - 21:00 Dinner healthcare facilities in Denmark O007 Katharina Olsen (Denmark) TUESDAY 16 APRIL 2013 Abbott Diagnostics iTK Diagnostics 14:30 - 14:45 Clostridium difficile 078 in pigs, a threat for Alere Health Labolutions farmers and employees ApDia Luminex 09:00 - 09:30 Registration O008 Liny Keessen Astellas Pharma Mediaproducts 14:45 - 15:00 Whole-genome sequencing reveals potential Bactimm Mediphos Medical Supplies 09:30 - 11:00 Plenary session interspecies transmission of Clostridium difficile type 078 Baseclear Merck Sharp & Dohme O009 Wilco Knetsch Becton Dickinson Meridian Bioscience Athene B/C Chair: Oscar Kuipers 15:00 - 15:15 Outbreaks of Clostridium difficile type 027 Beldico Minigrip Nederland 09:30 - 10:15 c-di-AMP, an essential signaling nucleotide in infections in nursing homes; tip of the iceberg? Gram-positive bacteria Bio Rad Laboratories MiPS O010 Sofie van Dorp Bio Trading Benelux MLS O001 Prof. Jörg Stülke, institut für Mikrobiologie und Genetik, Göttingen, Germany 15:15 - 15:30 Micro-array analysis and phenotypic character- Biognost MP Products ization of Clostridium difficile cell membrane BioMerieux Benelux Nimagen 10:15 - 11:00 From antigenic variation to base J in protease knock-out strains: reveals a possible trypanosomatids link to virulence Bodégro Novaveth O002 Prof. Piet Borst, NKi, Amsterdam O011 Dennis Bakker Boom Oxoid Bruker Nederland Panasonic Biomedical Sales europe 11:00 - 11:30 Coffee/tea break Room 2 Leishmaniasis: a curable disease? Cepheid Benelux Perkinelmer Chair: Titia Kortbeek Check-Points Pfizer 11:30 - 12:45 Plenary session & award ceremony Clindia Benelux Qiagen Benelux 14:00 - 14:30 Asymptomatic carriers in visceral leishmaniasis Diagenode Diagnostics R-Biopharm AG O012 epco Hasker (Belgium) DiaSorin Roche Diagnostics Nederland Athene B/C Chair: Menno de Jong 14:30 - 15:00 Effectiveness of treatment of visceral elitech Benelux ServiceXS 11:30 - 12:15 Host switches and evolution: news from viral reservoir investigations leishmaniasis eppendorf Nederland Siemens Healthcare Diagnostics O003 Prof. Christian Drosten, institute of O013 Koert Ritmeijer Gilead Sciences Netherlands Softmedex Solutions Virology – university of Bonn Medical Centre, 15:00 - 15:15 Therapy for leishmaniasis in returning Greiner Bio-One Technologiestichting STW Bonn, Germany travellers Hettich Benelux unilever Vlaardingen 12:15 - 12:45 Award ceremony O014 Caspar Hodiamont Hologic Netherlands 15:15 - 15:30 Leishmaniasis in the Netherlands 2005-2012: 12:45 - 14:00 Lunch epidemiology, diagnostic techniques and sequence-based species typing in 192 patients O015 Aldert Bart Athene A 13:00 - 14:00 NVvM Business meeting Room 4/5 Intestinal microbes and host interplay Chairs: Peter van Baarlen & Clara Belzer 14:00 - 15:30 Parallel sessions 14:00 - 14:30 Adaptive immunity, microbiota composition and prevention of pathobiont outgrowth in Athene B/C New challenges in infection prevention zebrafish Chair: Greet Vos O016 Sylvia Brugman 14:00 - 14:30 A nosocomial outbreak of VIM-positive 14:30 - 15:00 The gut microbiome using metagenomics and Pseudomonas aeruginosa: problems and dedicated bioinformatics pitfalls O017 Jeroen Raes O004 Juliette Severin 15:00 - 15:15 The effect of viral, bacterial and parasitic 14:30 - 15:00 From guidelines to implementation: do we pathogens on the intestinal microbiota need fasces? O018 Dries Budding